Table 5. . Results of the CEA per event avoided.
| Event type | Study group | Total cost† | Percentage of patients with event | Effect.‡ | Incremental cost | Incremental effect. | NNT§ | ICER | Total cost/ event avoided¶ |
|---|---|---|---|---|---|---|---|---|---|
| Stroke and systemic embolism | Api. | €2208 | 0.02 | 0.98 | €2253 | ||||
| Acen. | €2482 | 0.037 | 0.963 | -€274 | 0.017 | 59 | - €16,118 | €2577 | |
| Minor bleeding | Api. | €2208 | 0.072 | 0.928 | €2379 | ||||
| Acen. | €2482 | 0.109 | 0.891 | -€274 | 0.037 | 27 | - €7,405 | €2786 | |
| Major bleeding | Api. | €2208 | 0.024 | 0.976 | €2262 | ||||
| Acen. | €2482 | 0.046 | 0.954 | -€274 | 0.022 | 46 | - €12,455 | €2602 |
†
Total corrected cost including healthcare and non-healthcare costs.
‡
Estimated as the percentage of patients without events.
§
Estimated as the number of patients needed to treat to prevent one additional event.
¶
Estimated as the total cost divided by the effectiveness.
Acen: Acenocoumarol; Api: Apixaban; CEA: Cost–effectiveness analysis; ICER: Incremental cost–effectiveness ratio; NNT: Number of patients needed to treat.